SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Pictured: Photo illustration of hundred dollar bill and graph
Business
Nvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna Execs
A pair of biotechs burst onto the scene Tuesday, exiting stealth with $100 million in financing each and tapping executives who made their names at bluebird bio and Karuna Therapeutics.
April 9, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Nasdaq signage and building in New York City
Deals
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials
Contineum Therapeutics priced its initial public offering Friday, scaling back its expectations for gross proceeds of $110 million for clinical trials of a challenger to Boehringer Ingelheim and Roche.
April 5, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Facade of the FDA's office in Maryland
FDA
Basilea Wins FDA Approval for Antibiotic Ending 15-Year Regulatory Quest
Basilea Pharmaceutica received FDA approval for its antibiotic Zevtera in three indications Wednesday, finally getting the drug across the finish line a decade and a half after the agency rejected an earlier submission.
April 4, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Person undergoing an eye exam
Drug Development
Roivant Posts Phase II Eye Disease Win for TYK2 Drug, Plans Pivotal Program
Roivant has chalked up a mid-stage victory for its Pfizer-partnered dual TYK2/JAK1 inhibitor, setting it up to start a Phase III trial in non-anterior non-infectious uveitis this year.
April 2, 2024
 · 
2 min read
 · 
Nick Paul Taylor
External view of AstraZeneca's production plant in Sweden
FDA
AstraZeneca Gets FDA Approval in Boost to Rare Disease Franchise
AstraZeneca has secured the FDA’s green light for Voydeya, a first-in-class, oral, Factor D inhibitor developed as an add-on to its standard-of-care Ultomiris or Soliris for certain patients with paroxysmal nocturnal haemoglobinuria.
April 1, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Close-up of a skin lesion in a patient w
Deals
Avalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivot
Avalo Therapeutics rolled the dice on a big pivot Wednesday, acquiring AlmataBio and focusing on the biotech’s ex-Eli Lilly hidradenitis suppurativa candidate over its existing assets.
March 29, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Gene therapy illustration showing an inj
Drug Development
Nanoscope Claims Phase II Win for Gene Therapy After Changing Primary Endpoint
Nanoscope Therapeutics nabbed a victory on the changed primary endpoint of its Phase IIb vision loss gene therapy trial Tuesday, teeing the biotech up to file for FDA approval of the candidate this year.
March 27, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Healthcare worker holding up a vial for an LDL-C test
FDA
Esperion Targets Seven-Fold Jump in Cholesterol Drug Population with FDA Label Expansion
Esperion bagged broader-than-expected FDA labels for its cholesterol-busting drugs Friday, allowing the biotech to target seven times as many people in the U.S. compared to the old labels.
March 25, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Bayer's global pharmaceuticals headquarters in Germany
Business
Bayer’s Prostate Cancer Drug Nubeqa on Track to Generate Blockbuster Sales in 2024
At Thursday’s Pharma Media Day, Bayer touted Nubeqa as the fastest growing androgen receptor inhibitor in the U.S., which will achieve blockbuster status this year.
March 22, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Bristol Myers Squibb office in California
Drug Development
BMS Racks Up Phase III Win in Liver Cancer Targeted by AstraZeneca and Roche
Bristol Myers Squibb secured another late-phase immuno-oncology victory Wednesday, showing that the combination of Opdivo and Yervoy improved overall survival in a patient population served by rival checkpoint inhibitors from AstraZeneca and Roche.
March 20, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Bayer's office in Berlin, Germany/iStock
Drug Development
Bayer’s Veozah Rival Hits Goals in Long-Term Phase III Hot Flash Study
Bayer bagged another late-stage victory for its menopause drug candidate Tuesday, setting up a potential showdown with Astellas’ Veozah which was approved last year by the FDA for the treatment of hot flashes.
March 19, 2024
 · 
2 min read
 · 
Nick Paul Taylor
External view of AstraZeneca's production plant in Sweden
Drug Development
AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need
AstraZeneca reported Monday that adding Lynparza to Imfinzi improved outcomes in mismatch repair proficient endometrial cancer, more than doubling the median duration of response in patients.
March 18, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Entrance to Vertex's office in Boston, Massachusetts
Policy
Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value
The U.K. National Institute for Health and Care Excellence on Thursday recommended against funding Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Casgevy unless uncertainties can be cleared up.
March 14, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: 3D illustration of a damaged liver/iStoc
Drug Development
Ionis’ Antisense Molecule Hits Primary Endpoint in Phase II MASH Trial
The biotech announced Wednesday that patients on ION224 had histologic improvement in the liver disease without worsening of fibrosis. Ionis’ mid-stage win comes as the FDA is set to decide whether to approve rival Madrigal’s resmetirom by Thursday.
March 13, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Merck Research Laboratories in South San Francisco, California
Business
Merck Bets Potential $1B on Pearl Bio’s Genomically Recoded Organisms
Synthetic biology company Pearl Bio announced Tuesday it has entered into a license and collaboration agreement with Merck to discover biologic therapies comprising non-standard amino acids.
March 12, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Load More